Fact Checked

SurvivorNet Fact Checking and Medical Review Standards:  

The SurvivorNet News Team creates high quality medical information that complies with our industry leading standards for factual accuracy and sourcing from leading experts at academic medical institutions. Every news article is thoroughly fact-checked by our physician collaborators. We vet each piece of work for factual integrity, impartiality, and clearly label any professional conflicts.

All SurvivorNet articles adhere to the following standards:

  1. All studies and research papers cited are from reputable academic medical institutions or peer-reviewed journals.
  2. When we use data, statistics, or quotes these references link to the original source.
  3. All content related to new treatments, drugs, procedures, and so on must clearly describe availability, side effects, treatment target (such as triple negative breast cancer)
  4. All medical information on SurvivorNet is sourced from respected medical professionals with verified medical credentials and links are provided to these sources.
  5. We strive to give the reader relevant background information and include, clearly-sourced contextual health information in all articles. Readers are clearly alerted to any conflicts of interest from a medical source or the authors of a cited study.
/ Updated March 31st, 2022

Immunotherapy Vaccine for Late-Stage Prostate Cancer

NOW
PLAYING
Overview of Stage Four Lung Cancer
NOW
PLAYING
Clinical Trials and What Statistics Really Mean
NOW
PLAYING
Radiation for Advanced Lung Cancer
NOW
PLAYING
Immunotherapy Has Changed The Game For Lung Cancer
NOW
PLAYING
What Do Checkpoint Inhibitors Do For Cancer?
NOW
PLAYING
New Data at ASCO: Encouraging Results For Immunotherapy in Advanced Non-Small Cell Lung Cancer

Later Stage Treatment: New Treatment Developments

SEE MORE   

  • There are several new drugs and treatment options available for those facing advanced stage prostate cancer.
  • Two PARP inhibitors are currently FDA-approved: Lynparza (olaparib) and Rubraca (rucaparib).
  • Two newer androgen deprivation therapies include: Xtandi (enzalutamide) Erleada (apalutamide).

Later Stage Treatment: New Treatment Developments

  • There are several new drugs and treatment options available for those facing advanced stage prostate cancer.
  • Two PARP inhibitors are currently FDA-approved: Lynparza (olaparib) and Rubraca (rucaparib).
  • Two newer androgen deprivation therapies include: Xtandi (enzalutamide) Erleada (apalutamide).
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.